Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic

At the beginning of the year, Dren Bio penned a deal with Pfizer for a potential $1 billion for its bispecific antibody platform. The details surrounding the deal were sparse, and the details on Dren Bio’s platform sparser.